Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification.

Jaffe JD, Keshishian H, Chang B, Addona TA, Gillette MA, Carr SA.

Mol Cell Proteomics. 2008 Oct;7(10):1952-62. doi: 10.1074/mcp.M800218-MCP200. Epub 2008 Jun 4.

2.

Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution.

Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA.

Mol Cell Proteomics. 2007 Dec;6(12):2212-29. Epub 2007 Oct 15.

3.

Enhanced sensitivity and multiplexing with 2D LC/MRM-MS and labeled standards for deeper and more comprehensive protein quantitation.

Percy AJ, Simon R, Chambers AG, Borchers CH.

J Proteomics. 2014 Jun 25;106:113-24. doi: 10.1016/j.jprot.2014.04.024. Epub 2014 Apr 24.

PMID:
24769237
4.

Protocol for Standardizing High-to-Moderate Abundance Protein Biomarker Assessments Through an MRM-with-Standard-Peptides Quantitative Approach.

Percy AJ, Yang J, Chambers AG, Mohammed Y, Miliotis T, Borchers CH.

Adv Exp Med Biol. 2016;919:515-530. Review.

PMID:
27975233
5.

MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides.

Yang X, Lazar IM.

BMC Cancer. 2009 Mar 27;9:96. doi: 10.1186/1471-2407-9-96.

6.

Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.

Lopez MF, Kuppusamy R, Sarracino DA, Prakash A, Athanas M, Krastins B, Rezai T, Sutton JN, Peterman S, Nicolaides K.

J Proteome Res. 2011 Jan 7;10(1):133-42. doi: 10.1021/pr100153j. Epub 2010 Jun 4.

PMID:
20499897
8.

Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS (LC-MRM-MS).

Abbatiello SE, Mani DR, Schilling B, Maclean B, Zimmerman LJ, Feng X, Cusack MP, Sedransk N, Hall SC, Addona T, Allen S, Dodder NG, Ghosh M, Held JM, Hedrick V, Inerowicz HD, Jackson A, Keshishian H, Kim JW, Lyssand JS, Riley CP, Rudnick P, Sadowski P, Shaddox K, Smith D, Tomazela D, Wahlander A, Waldemarson S, Whitwell CA, You J, Zhang S, Kinsinger CR, Mesri M, Rodriguez H, Borchers CH, Buck C, Fisher SJ, Gibson BW, Liebler D, Maccoss M, Neubert TA, Paulovich A, Regnier F, Skates SJ, Tempst P, Wang M, Carr SA.

Mol Cell Proteomics. 2013 Sep;12(9):2623-39. doi: 10.1074/mcp.M112.027078. Epub 2013 May 20.

9.
10.

Establishing a reliable multiple reaction monitoring-based method for the quantification of obesity-associated comorbidities in serum and adipose tissue requires intensive clinical validation.

Oberbach A, Schlichting N, Neuhaus J, Kullnick Y, Lehmann S, Heinrich M, Dietrich A, Mohr FW, von Bergen M, Baumann S.

J Proteome Res. 2014 Dec 5;13(12):5784-800. doi: 10.1021/pr500722k. Epub 2014 Nov 17.

PMID:
25318410
11.

Qualification and Verification of Protein Biomarker Candidates.

Zhao Y, Brasier AR.

Adv Exp Med Biol. 2016;919:493-514. Review.

PMID:
27975232
12.

Technical considerations for large-scale parallel reaction monitoring analysis.

Gallien S, Bourmaud A, Kim SY, Domon B.

J Proteomics. 2014 Apr 4;100:147-59. doi: 10.1016/j.jprot.2013.10.029. Epub 2013 Nov 4.

PMID:
24200835
13.
14.

Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution.

Keshishian H, Addona T, Burgess M, Mani DR, Shi X, Kuhn E, Sabatine MS, Gerszten RE, Carr SA.

Mol Cell Proteomics. 2009 Oct;8(10):2339-49. doi: 10.1074/mcp.M900140-MCP200. Epub 2009 Jul 13.

15.

Rapid verification of candidate serological biomarkers using gel-based, label-free multiple reaction monitoring.

Tang HY, Beer LA, Barnhart KT, Speicher DW.

J Proteome Res. 2011 Sep 2;10(9):4005-17. doi: 10.1021/pr2002098. Epub 2011 Jul 26.

16.

MRM validation of targeted nonglycosylated peptides from N-glycoprotein biomarkers using direct trypsin digestion of undepleted human plasma.

Lee JY, Kim JY, Cheon MH, Park GW, Ahn YH, Moon MH, Yoo JS.

J Proteomics. 2014 Feb 26;98:206-17. doi: 10.1016/j.jprot.2014.01.003. Epub 2014 Jan 14.

PMID:
24434586
17.

High-throughput liquid chromatography/mass spectrometry method for the quantitation of small molecules using accurate mass technologies in supporting discovery drug screening.

Ding X, Ghobarah H, Zhang X, Jaochico A, Liu X, Deshmukh G, Liederer BM, Hop CE, Dean B.

Rapid Commun Mass Spectrom. 2013 Feb 15;27(3):401-8. doi: 10.1002/rcm.6461.

PMID:
23280971
18.

MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum.

Chambers AG, Percy AJ, Simon R, Borchers CH.

Expert Rev Proteomics. 2014 Apr;11(2):137-48. doi: 10.1586/14789450.2014.877346. Epub 2014 Jan 29. Review.

PMID:
24476379
19.

Metrological traceability in mass spectrometry-based targeted protein quantitation: a proof-of-principle study for serum apolipoproteins A-I and B100.

Smit NP, Romijn FP, van den Broek I, Drijfhout JW, Haex M, van der Laarse A, van der Burgt YE, Cobbaert CM.

J Proteomics. 2014 Sep 23;109:143-61. doi: 10.1016/j.jprot.2014.06.015. Epub 2014 Jun 25.

PMID:
24972322
20.

Simplified and efficient quantification of low-abundance proteins at very high multiplex via targeted mass spectrometry.

Burgess MW, Keshishian H, Mani DR, Gillette MA, Carr SA.

Mol Cell Proteomics. 2014 Apr;13(4):1137-49. doi: 10.1074/mcp.M113.034660. Epub 2014 Feb 11.

Supplemental Content

Support Center